glp-1 therapies success rate Q&A: Long-term of hinges on more than just a prescription Market Overview: GLP-1 Agonists and

GLP-1 RAs have also been found to reduce the risk of acute and chronic kidney disease, cardiovascular events, liver disease, sepsis, and substance use disorders

Combining SGLT2 inhibitors with conventional treatments could enhance treatment efficacy and improve patient outcomes (Basak et al., 2023)

It is majorly found circulating in the blood as GLP-1(7-36) amide that is produced primarily from three tissues of the human body: enteroendocrine L cells in the distal small bowel, cells in the pancreas, and the central nervous system ( Surprisingly, it took approximately 20 years from the discovery of GLP-1 to the authorized approval of worldwide utilized GLP-1 RAs

This work was supported by the Cangzhou Science and Technology Plan Self-financed Project (2023-202423244102075), the Military Key Discipline Construction Projects of China (HL21JD1206), and the National Natural Science Foundation of China (82401967)

Patients report fewer overlapping side effects, but appetite and cravings often return during the gap week